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PURPOSE. Ocular trauma is common in civilian and military populations. Among other injuries,
closed globe blunt ocular trauma causes acute disruption of photoreceptor outer segments
(commotio retinae) and retinal ganglion cell (RGC) death (traumatic optic neuropathy
[TON]), both of which permanently impair vision. Caspase-2-dependent cell death is
important and evidenced in models of RGC degeneration. We assessed the role of caspase-2 as
a mediator of RGC and photoreceptor death in a rat blunt ocular trauma model.
METHODS. Bilateral ballistic closed globe blunt ocular trauma was induced in female Lister-
hooded rats and caspase-2 cleavage and localization assessed by Western blotting and
immunohistochemistry. Retinal caspase-2 was knocked down by intravitreal injection of
caspase-2 small interfering RNA (siCASP2). In retinal sections, RGC survival was assessed by
BRN3A-positive cell counts and photoreceptor survival by outer nuclear layer (ONL)
thickness, respectively. Retinal function was assessed by electroretinography (ERG).
RESULTS. Raised levels of cleaved caspase-2 were detected in the retina at 5, 24, and 48 hours
after injury and localized to RGC but not photoreceptors. Small interfering RNA–mediated
caspase-2 knockdown neuroprotected RGC around but not in the center of the injury site. In
addition, caspase-2 knockdown increased the amplitude of the ERG photopic negative
response (PhNR) at 2 weeks after injury. However, siCASP2 was not protective for
photoreceptors, suggesting that photoreceptor degeneration in this model is not mediated
by caspase-2.
CONCLUSIONS. Caspase-2 mediates death in a proportion of RGC but not photoreceptors at the
site of blunt ocular trauma. Thus, intravitreally delivered siCASP2 is a possible therapeutic for
the effective treatment of RGC death to prevent TON.
Keywords: traumatic optic neuropathy, commotion retinae, retinal ganglion cells, caspase-2,
photoreceptors
Ocular injuries are common, occurring in up to 10% of allmilitary casualties1 and with a lifetime prevalence of
20% in civilian populations.2 Traumatic optic neuropathy
(TON) occurs with an annual incidence of 1/1,000,000 in the
civilian population,3 but occurs in up to 20% of military eye
injuries.4
TON is defined as retinal ganglion cell (RGC) death and
axon degeneration caused by head or eye injury.5 RGCs
populate the inner retina and their axons form the optic
nerve (ON). RGCs are central nervous system (CNS) neurons
that lack an endogenous regenerative capacity. Thus, after
injury or disease, lost RGCs are not replaced, and the
damaged ON does not regenerate, leading to irreversible
visual loss.6–8 The ON may be injured either directly (e.g.,
penetrating ocular injury, bony fragment damage within the
optic canal, and ON sheath hematomas) or indirectly after
traumatic head or eye injury (e.g., blunt eye injury and
blast).9–12 Blunt ocular trauma also damages other retinal
cells, causing commotio retinae, characterized by photore-
ceptor degeneration.13 TON can be studied using animal
models replicating blunt and blast ocular injuries14,15 and ON
crush (ONC).16–18 TON causes permanent visual loss and
there are currently no effective treatments to preserve or
restore vision.19,20 After blunt ocular trauma, initiator
caspase-9 is activated and initiates localized photoreceptor
death, which can be attenuated in the lesion penumbra of
animal models by caspase-9 inhibition.21 However, the
mechanisms of the accompanying RGC death in this model
have not been defined and no treatment has been shown to
neuroprotect RGCs after blunt ocular trauma.22
RGCs die by caspase-dependent mechanisms as part of
normal development, degenerative disease, and after ON
trauma.23 Caspases are cysteine aspartate proteases that induce
apoptosis through initiator and executioner family members.
Initiator caspases (2, 8, 9, and 10) activate executioner caspases
(3, 6, and 7) through catalytic cleavage of their activation
domain.24–26 Caspase-2 is not part of the canonical intrinsic
(caspase-9–mediated) or extrinsic (caspase-8–mediated) apo-
ptotic pathways, is highly evolutionarily conserved and can be
activated by DNA damage, heat shock, endoplasmic reticulum
stress, and oxidative stress.27–31 Caspase-2 is activated by
cleavage and subsequent dimerization; it is therefore possible
to use the presence of cleaved caspase-2 as a marker for its
activation.32
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We have previously shown that RGC death after ONC is
caspase-2–mediated. For example, axotomized RGC activate
caspase-2, whereas pharmacological inhibition protects ~60%
of RGC for up to 21 days after ONC and a chemically modified
synthetic short interfering RNA (siRNA) against caspase-2
(siCASP2) protects >95% of RGCs for up to 12 weeks.33–36
siCASP2 also protects RGC in a mouse optic neuritis model.37
siCASP2 (also known as QPI-1007) is currently in clinical trials
for nonarteritic ischemic optic neuropathy (NAION) (protocol:
QRK007 NCT01064505) and acute primary angle-closure
glaucoma (protocol: QRK208 NCT01965106) with Quark
Pharmaceuticals (Ness Ziona, Israel). Caspase-2 is also activated
and induces neuronal degeneration after spinal cord injury
(SCI)38 and in Alzheimer’s disease.39,40
In this study, we have discriminated between the caspase-9–
mediated photoreceptor loss and RGC death by demonstrating
that caspase-2 mediates the RGC but not photoreceptor
degeneration in a rat blunt ocular injury model, and that
siCASP2 structurally and functionally protected RGCs but not
photoreceptors.
MATERIALS AND METHODS
Experimental Design
To determine the role of caspase-2 in RGCs and photoreceptors
after blunt eye injury, groups of rats were subjected to
unilateral or bilateral blunt eye injury under anaesthesia as a
recovery procedure. To determine caspase-2 cleavage and
protein localization, Western blotting and immunohistochem-
istry (IHC) were performed at 5, 24, and 48 hours after injury
(Fig. 1A). siCASP2 was used to knockdown caspase-2 and
electroretinography (ERG) and cell counting in retinal sections
used to determine RGC and photoreceptor survival and
restitution of function (Fig. 1B).
Animal Care and Procedures
Animal procedures were licensed by the UK Home Office,
approved by the University of Birmingham’s Animal Welfare
and Ethical Review Committees and conducted in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic
FIGURE 1. Experimental design of (A) in vivo protein and IHC studies and (B) in vivo siCASP2 studies.
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and Vision Research. A total of 68 animals were used in this
study (Fig. 1). Female Lister-hooded rats weighing 170 to 200 g
were purchased from Charles River Laboratories (Margate,
UK), kept on a 12-hour light-dark cycle with a daytime
luminance of 80 lux and fed and watered ad libitum. Surgery
and ERG recording were performed under inhalational
anaesthesia with 3% isoflurane in oxygen (2% for ERG studies).
Blunt injury was induced as previously described,41 using a
0.095-g spherical plastic pellet fired using compressed air to
directly impact the inferior scleral surface at a speed of 20 m/s.
This creates a localized retinal injury causing 18.4% photore-
ceptor degeneration by 2 weeks and extensive loss of
photoreceptor function, with ERG amplitude reduced to
<50% of intact values.41
Western Blot
Groups of rats were killed at 5, 24, and 48 hours after bilateral
blunt injury, as well as uninjured control animals, by overdose
of anaesthetic (n ¼ 3 animals per group, six pooled retinae,
repeated on three independent occasions; total nine animals
per group, 18 retinae). Whole retinae were removed, pooled,
and protein extracted in ice-cold lysis buffer (150 mM NaCl, 20
mM Tris, 1 mM EDTA, 0.5 mM EGTA, 1% NP-40, pH 7.4)
supplemented with protease inhibitor cocktail (Sigma, Poole,
UK), denatured by heating to 908C for 5 minutes, separated on
a Tris-glycine SDS gels with 40 lg protein/lane and transferred
to a polyvinylidene fluoride (PVDF) membrane (Millipore,
Watford, UK). After probing with primary and secondary
antibodies specific protein bands were detected by exposure
to photographic film (GE Healthcare, Little Chalfont, UK). Blots
were repeated on three independent occasions. Integrated
band intensity was measured using the automated gel analysis
feature in ImageJ (http://imagej.nih.gov/ij/; provided in the
public domain by the National Institutes of Health, Bethesda,
MD, USA) and displayed as % loading control signal (b-actin) 6
SEM.
Tissue Preparation for IHC
At 5 and 48 hours after unilateral blunt injury, four rats in each
group were killed by intracardiac perfusion with 4% parafor-
maldehyde (PFA) in PBS. The inferior limbus was marked with
a 6.0 Vicryl suture (orientating the injury site). The anterior
segment was removed, the injury site identified under light
microscopy, and a small section of retina and sclera removed at
the 3 and 9 o’clock positions (injury site at 12 o’clock) to allow
precise orientation during the embedding process. Retinal
cups were cryoprotected in ascending concentrations of
sucrose (10%, 20%, 30%) in PBS at 48C before embedding in
optimum cutting temperature medium and storage at 808C.
Sections were cut in a plane parallel to that running between
the center of the injury site and the optic disc (Supplementary
Fig. 1) at a thickness of 15 lm using a cryostat (Brights
Instruments, Huntingdon, UK) and adhered onto Superfrost
(Fisher Scientific, Loughborough, UK) coated glass microscope
slides and stored at208C until required.
Immunohistochemistry
Frozen sections were left to thaw for 20 minutes and washed 3
3 5 minutes in PBS, followed by 20 minutes of permeabiliza-
tion and nonspecific binding site blocking in 1% Triton X-100
(Sigma) and 3% bovine serum albumin (BSA; Sigma). Tissue
sections were incubated overnight at 48C with primary
antibody (Table) in 0.5% Tween-20 and 3% BSA before washing
335 minutes in PBS and incubating with secondary antibodies
(Table) at room temperature. Tissue sections were washed 33
5 minutes in PBS then mounted in VectorShield mounting
medium containing 40,6-diamidino-2-phenylindole (DAPI) (Vec-
tor Laboratories, Peterborough, UK). Controls with omitted
primary antibody were included in each run and these were
used to set the background threshold levels for image capture.
Sections were viewed under an epi-fluorescent microscope
equipped with an AxioCam HRc, controlled using Axiovision
Software (all from Zeiss, Hertfordshire, UK).
Antibodies
Primary antibodies used were against full-length caspase-2 for
IHC (AB2251; Abcam, Cambridge, UK), full-length and cleaved
caspase-2 (H19) for Western blotting and IHC (SC-623, Santa
Cruz, CA), BRN3A (C-20) to detect RGCs in IHC (SC-31984;
Santa Cruz, CA) and b-actin as a Western blot loading control
(A5441; Sigma, Poole, UK). Secondary antibodies were species-
specific horseradish peroxidase conjugated for Western blot-
ting (GE Healthcare) and Alexa Fluor 488 or 594-conjugated for
IHC (Invitrogen, Paisley, UK). Antibodies used are displayed in
the Table.
Intravitreal Injections of siCASP2/siEGFP
siCASP2 (a gift from Quark) was reconstituted in sterile PBS
and 5 lL of 4 mg/mL solution delivered by unilateral
intravitreal injection immediately after and at 7 days after
bilateral blunt ocular injury (Fig. 1, n ¼ 8 eyes from eight
animals). Contralateral eyes were given control treatment of 5
lL of 4 mg/mL siEGFP (enhanced green fluorescent protein;
TABLE. Antibodies Used in IHC and Western Blotting
Antigen Dilution Supplier Catalog No. To Identify
Caspase-2 (H-19) 1:500 (WB); Santa Cruz Biotechnology
(Santa Cruz, CA, USA)
SC-623 Full-length and cleaved
fragments
b-actin 1:10,000 (WB) Sigma (Poole, UK) A5441 Loading control
Caspase-2 1:200 (IHC) Abcam (Cambridge, UK) AB2251 Full-length caspase-2
BRN3A (C-20) 1:200 (IHC) Santa Cruz SC-31984 RGC-specific transcription
factor
Donkey anti-goat IgG Alexa Fluor 594 1:400 (IHC) Invitrogen, (Paisley, UK) A11058 Goat IgG
Donkey anti-rabbit IgG Alexa Fluor 488 1:400 (IHC) Invitrogen A-21206 Rabbit IgG
Donkey anti-rabbit IgG Alexa Fluor 594 1:400 (IHC) Invitrogen A-21207 Rabbit IgG
Anti-rabbit IgG, HRP-linked 1:1,000 (WB) Cell Signaling Technology
(Danvers, MA, USA)
7074S Rabbit IgG
Anti-mouse IgG, HRP-linked 1:1,000 (WB) Cell Signaling Technology
(Danvers, MA, USA)
7076S Mouse IgG
HRP, horseradish peroxidase; WB, Western blot.
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gift from Quark) solution. Uninjured rats were culled without
intravitreal injections as intact controls (n ¼ 8 animals). Rats
were culled 14 days after injury and eyes processed in the same
way as for IHC.
Electroretinography
Electroretinograms (ERG) were recorded (HMsERG; Ocu-
science, Kansas City, MO, USA) at 7 and 14 days after injury
and in uninjured controls and were interpreted using ERG
View (Ocuscience). Animals were dark-adapted overnight and
prepared for ERG under dim red light (>630 nm). Scotopic
(dark-adapted) flash ERG were recorded from 2.5 to þ1 log
units with respect to standard flash in half log unit steps and
photopic (light-adapted) flash ERG were recorded with
background illumination of 30,000 mcd/m2 over the same
range. DTL fiber (Unimed Electrode Supplies, Farnham, UK)
corneal electrodes with pressure-moulded Aclar (Agar Scien-
tific, Stansted, UK) contact lenses were used with needle skin
electrodes (Unimed).
ERG traces were analyzed using the manufacturer’s semi-
automated software ERGView (Ocuscience) and marker
position manually verified and adjusted where necessary by a
blinded observer.
Assessment of Photoreceptor and RGC Survival
Outer nuclear layer (ONL) thickness was measured in frozen
sections as previously described.21 To account for variability in
cell death with respect to distance from the impact site, seven
retinal sections per eye were analyzed from each eye: one
through the optic disc and center of the impact site (0 lm) and
in two sections at 600, 1200, and 1800 lm either side of this
plane (see Supplementary Fig. S1). DAPI-stained sections were
scanned and the ONL manually segmented in Adobe Photo-
shop (Adobe Systems, Inc., San Jose, CA, USA) by a masked
observer and the ONL area, measured in ImageJ, divided by the
length of the retinal segment to give an average ONL thickness.
Because the ONL contains only photoreceptor nuclei, this
method assesses photoreceptor survival with systematic
sampling across the whole retina.
Similarly, RGC survival was measured by counting cells in
the ganglion cell layer (GCL) stained for brain-specific
homeobox/POU domain protein 3A (BRN3A; an RGC-specific
transcription factor and marker)42,43 across the entire retinal
section at the same distances from the center of the injury site
(0, 600, 1200, and 1800 lm).
Only the central section is a radial section through the
injury site. Sections cut tangentially through the circular zones
of injury at the periphery of the injury site will overrepresent
cells in these peripheral zones, whereas the single section
through the disc and the center of the injury site passes
perpendicularly through these zones and so they are propor-
tionally less represented in the overall count for that section.
Statistics
Power calculations performed in G*Power (v. 3.1.4; Kiel
University, Kiel, Germany) indicated for Western blot, n ¼ 3
animals (six pooled eyes) per time point had 82% power to
detect a 1-fold change in protein levels (assuming SD ¼ 20%
band intensity); for ERG assessment (more variable than
structural measures, therefore less powerful) eight animals
had a power of 88% to detect a moderate (f¼ 0.25) treatment
effect (correlation among repeated measures ¼ 0.5 from past
data41).
All statistical analyses were performed in SPSS 21 (IBM
Corp., Armonk, NY, USA). Western blots were analyzed using
repeated-measures ANOVA with Tukey post hoc testing. ERG,
BRN3A counts, and ONL thickness data were analyzed by
fitting a generalized linear model. T-tests with Holms Bonferro-
ni correction were applied after generalized linear model for
explanatory purposes only, as no meaningful post hoc test was
available within subject comparison. Average values are
presented as mean 6 SEM.
RESULTS
Caspase-2 Is Cleaved in RGC After Blunt Ocular
Injury
Western blotting for caspase-2 and its cleaved fragments was
performed on pooled retinae after bilateral blunt ocular injury
(n ¼ 3 animals per experimental group, six pooled retinae,
repeated on three independent occasions; total nine animals
per group, 18 retinae). Western blotting of whole retinal
lysates demonstrated that retinal levels of the cleaved 12-kDa
fragment of caspase-2 increased up to 48 hours after injury
compared with intact animals (ANOVA P < 0.01; Figs. 2A, 2C),
though full-length 55-kDa caspase-2 levels remained unchanged
(ANOVA P > 0.05; Figs. 2A, 2B). Post hoc t-test with Tukey’s
multiple comparisons showed that cleaved caspase-2 signifi-
cantly increased at 48 hours after blunt ocular trauma
compared with intact controls (P < 0.05). There was also a
significant increase in 12-kDa caspase-2 fragment between 5-
hour and 48-hour timepoints (P < 0.001) and 24 and 48 hours
(P < 0.05).
Caspase-2 IHC was performed to demonstrate retinal
localization (n ¼ 4 animals per timepoint). At 5 and 48 hours
after blunt ocular injury, caspase-2 was localized to RGC
adjacent to the center of the injury site with increased
cytoplasmic caspase-2 expression compared to intact retinae
(Fig. 3A). Caspase-2 was also detected in the inner nuclear layer
(INL); however, levels were not altered by injury, suggesting
that caspase-2 is endogenously expressed in the INL. Immuno-
reactive caspase-2 was not detected by IHC in the ONL, where
photoreceptor cell bodies are present (Fig. 3B).
siCASP2 Protected RGC Adjacent to the Center of
the Injury Site But Did Not Protect Photoreceptors
To assess the effects siCASP2 treatment, bilateral blunt ocular
injury was performed with unilateral intravitreal injection of
siCASP2 and contralateral injection of siEGFP control (n ¼ 8
eyes per condition, eight animals); animals were culled at 2
weeks after injury and eyes processed for IHC. Intact animals
receiving no injections were also analyzed (n ¼ 8 animals).
siCASP2 treatment reduced RGC death with an effect that
varied by distance from the impact site (generalized linear
model P < 0.01) (Fig. 4A). For example, BRN3A cell counts as a
percentage of intact retinae at 0, 600, 1200, and 1800 lm from
the impact site were 73.94% 6 4.51%, 77.73% 6 2.61%,
84.70% 6 3.87%, and 84.64% 6 7.02% in siCASP2-treated eyes
compared with 67.39% 6 4.06%, 66.73% 6 2.57%, 82.66% 6
4.59%, and 85.26% 6 4.17% in siEGFP control eyes. Mean
counts of BRN3A-positive cells per 1000 lm of retinae for
intact, and after bilateral blunt injury with siCASP2 and siEGFP
injections are displayed in Figure 4C. Post hoc t-testing (with
Holms Bonferroni correction for multiple comparison) at each
distance, confirmed higher RGC counts immediately peripheral
to the impact site (600 lm; P < 0.05) in siCASP2-treated
compared with siEGFP control retinae, indicating a pro-
survival effect of caspase-2 knockdown on RGC in that zone
of injury. There was little effect of siCASP2 on RGC survival
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central to the impact site (0 lm) and distant to the injury site
(1200 and 1800 lm).
To assess the effect of siCASP2 on photoreceptor death in
the rat retina, we measured ONL thickness on retinal
sections at 600, 1200, and 1800 lm on either side of the
impact site as previously described21 and found no
significant effect of siCASP2 treatment on ONL thickness,
compared with siEGFP control (Fig. 4B; generalized linear
model P ¼ 0.372 for an effect of siCASP2, with no significant
variation by distance from impact site [P ¼ 0.942]). For
example, normalized percentages of intact ONL thickness at
0, 600, 1200, and 1800 lm from the impact site were
76.89% 6 9.40%, 74.60% 6 7.02%, 71.75% 6 7.86%, and
70.39% 6 8.16% in siCASP2-treated eyes compared with
73.81% 6 5.54%, 71.98% 6 6.39%, 65.41% 6 5.49%, and
70.5% 6 6.88% in siEGFP control eyes. Mean ONL thickness
values at different distances from the center of the impact
site in intact, and after bilateral blunt injury with siCASP2 or
siEGFP intravitreal injections are displayed in Figure 4D. This
suggests that the pro-survival effect of caspase-2 knockdown
was specific to RGC.
Caspase-2 Knockdown Induced Significant
Functional RGC Neuroprotection After Blunt
Ocular Trauma
Bilateral blunt ocular injury was performed with unilateral
intravitreal injection of siCASP2 and contralateral injection of
siEGFP control (n ¼ 8 eyes per condition, eight animals).
Scotopic and photopic electroretinography was performed at 2
weeks after injury to assess retinal function after siCASP2
treatment. Intact animals receiving no injections were also
analyzed (n ¼ 8 animals). There was a reduction in photopic
negative (PhNR) amplitude recorded in siEGFP-injected and
siCASP2-injected rats compared with those with intact retinae
(Fig. 5A), suggesting reduced RGC function after blunt ocular
trauma. There was a significant functional protection in PhNR
amplitudes in siCASP2- compared with siEGFP-treated animals
(Fig. 5A, generalized linear model P¼ 0.042), an effect that did
not significantly vary by stimulus intensity across the range
tested. Blunt ocular injury also decreased the scotopic a-wave
and b-wave and the photopic b-wave amplitudes when
compared to intact rats (Figs. 5B–D), but there was no
significant effect of siCASP2 treatment on these waveforms
(Figs. 5B–D; scotopic a, P ¼ 0.145; scotopic b, P ¼ 0.503;
photopic b, P ¼ 0.889), suggesting a specific effect on RGC
function.
DISCUSSION
Our model of blunt ocular trauma causes commotio retinae
and TON.41 It is established that photoreceptors structurally
and functionally degenerate in this model and there is a
reduction in the number of cells in the GCL at the center of
the impact site, with less death toward the periphery.41
Previous studies have shown that photoreceptor death is
mediated by caspase-9,21 but the mechanisms of RGC death
in this model have not been previously investigated. Here
we show that caspase-2 is immunolocalized to injured RGC
and that levels of the active form, cleaved caspase-2,
increased over 48 hours after blunt ocular trauma. Activated
caspase-2 induces RGC death in diverse models of RGC
degeneration, including ONC (direct TON),33–35 glaucoma,
FIGURE 2. Retinal cleaved caspase-2 is elevated up to 48 hours after blunt ocular injury. Animals received bilateral blunt ocular injury and retinae
were collected after 5, 24, and 48 hours. Caspase-2 protein expression was analyzed by Western blot. (A) Representative Western blot, showing full-
length caspase-2 and cleaved caspase-2. (B) Full-length caspase-2 (55 kDa) was not altered after blunt ocular trauma (ANOVA P < 0.05). (C) Cleaved
caspase-2 (12 kDa) was elevated up to 48 hours after blunt ocular trauma (ANOVA P < 0.01; post hoc t-test with Tukey’s multiple comparisons P <
0.05). n¼3 animals per group with bilateral blunt ocular injury, six pooled retinae, repeated on three independent occasions; total nine animals per
group, 18 retinae. Error bars represent SEM. *P < 0.05, ***P < 0.001.
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and optic neuritis.37 Inhibition of caspase-2 protects >95%
of RGCs from death after ONC.33,35 Our study with siCASP2
suggests that RGC death in TON induced by blunt ocular
trauma is caspase-2-dependent and suggests a new thera-
peutic treatment for this condition.
In contrast, caspase-2 did not immunolocalize to photore-
ceptors after blunt ocular trauma and caspase-2 knockdown
using siCASP2 did not affect photoreceptor survival, suggesting
that photoreceptor death is independent of caspase-2 and that
other mechanisms are responsible for photoreceptor death; for
example, caspase-9–dependent mechanisms.21
In models of ocular blast injury, caspase-1 and other cell
death molecules, including receptor interacting protein kinase
(RIPK) 1 and 3, are localized to Mu¨ller cells and the inner
nuclear and inner plexiform layers,44 which suggests different
cell death signaling pathways in an ocular blast injury model.
However, caspase-2 is consistently implicated in RGC death
after various types of insults.33,35–37 In agreement with our
assertion that caspase-2 is an important cell death mediator in
RGC, caspase-2 is also implicated in the neuronal death that
occurs in some neurodegenerative diseases, including models
of Alzheimer’s disease, where caspase-2 cleavage of tau impairs
cognitive and synaptic function and downregulation of
caspase-2 restores long-term memory,40 as well as in b-
amyloid–induced neurodegeneration in vitro.39
IHC is often used to demonstrate caspase activation using
antibodies against full-length enzymes, despite them not
showing caspase cleavage or activation. Another way to show
caspase activity is through the use of pharmacologic inhibitors
of caspases, such as z-VAD-fmk. However, the active sites of
these pharmacological inhibitors are nonspecific and have
cross-reactivity with other caspases and noncaspase targets,
such as calpains.45–48 In addition, pharmacological inhibition
of caspase-2 is not as efficient as RNA interference using
siCASP2 at attenuating RGC loss, protecting only 60% of RGC
from death at 21 days after ONC,36 compared with >95% RGC
protection achieved by siCASP2.33,35 By contrast, our use of
siRNA knockdown is highly specific to caspase-2, without
activating nonspecific innate immunity33 and our study of
caspase-2 cleavage products ensures that cleaved caspase-2 is
present.
Previous studies have extensively studied the effects of
siCASP2 in vitro and in vivo after ONC.33 siCASP2 shows a
significant knockdown of caspase-2 mRNA in vitro using
quantitative PCR; with a >80% knockdown in human HeLa
cells and an approximately 65% knockdown in rat PC12 cells.
Also, in vivo there was an approximately 50% knockdown of
FIGURE 3. Caspase-2 (red) is localized to RGCs (green) but not to photoreceptors. (A) Caspase-2 (red) is localized to BRN3A- (green, an RGC-
specific transcription factor) positive cells in the GCL. Caspase-2 is present at 5 and 48 hours after injury, but is less present in intact retinae. (B)
Caspase-2 is not localized to photoreceptor cell bodies in the outer nuclear layer (ONL). There is caspase-2 immunostaining in the INL, but this is
not altered at 5 and 48 hours after blunt ocular injury. Nuclei were counterstained with DAPI (blue). (A) Scale bar: 20 lm. (B) Intact, scale bar: 100
lm; 5-hour and 48-hour scale bar: 50 lm. n¼ 4 animals per group.
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caspase-2 mRNA in Thy1.1 isolated RGC after intravitreal
injection of siCASP2 compared with siEGFP-injected controls;
however, these differences did not reach statistical signifi-
cance. It also has specific RNAi-mediated caspase-2 mRNA
cleavage, as shown through RNA ligase-mediated rapid
amplification of cDNA ends (RLM-RACE) experiments, which
show the detection of caspase-2 mRNA-specific cleavage
product.33 Further, siCASP2 has chemical modifications in
both sense and antisense strands, which prevent its degrada-
tion by vitreal and serum nucleases.33 siCASP2 does not
activate the innate immune system, shown through a lack of in
vivo interferon responses and in vitro cytokine production33
and has low-risk systemic toxicity.49 Together, these data
suggest that siCASP2 knocks down caspase-2 in vitro and in
vivo, does not induce an inflammatory response, and has
specific RNA interference-mediated cleavage of caspase-2.
After blunt ocular trauma, siCASP2 protected RGC from
death adjacent to the impact site, suggesting that this is where
the highest proportion of RGCs undergoing caspase-2–depen-
dent cell death are found. In contrast, RGC central to the
impact site, where more severe injury presumably predisposes
cells to necrosis, were less susceptible to modulation by
altered caspase-2 activity. Only a proportion of degenerating
RGCs in the immediate periphery of the lesion site were
protected by siCASP2, suggesting that the remaining propor-
tion die by alternative cell death mechanisms (such as
necroptosis or pyroptosis) or unregulated necrosis, which
remains to be elucidated. At greater distances from the impact
site, less RGC degeneration occurs, so no effect of siCASP2 was
seen.
The differential protection of retinal neurons by siCASP2
was also reflected by preservation of their function. The
scotopic a-wave is the first negative deflection of the flash ERG
wave and is predominantly caused by photoreceptor hyper-
polarization. In rats, the scotopic a-wave amplitude represents
rod function. siCASP2 did improve the scotopic a-wave, which
FIGURE 4. siCASP2 prevents RGC death but does not protect photoreceptors. (A) BRN3A- (RGC-specific transcription factor) positive RGCs were
counted across the entire retinae and reported as a percentage of intact BRN3A counts per 1000 lm of retinae. Unilateral intravitreal injection of
siCASP2 promoted RGC survival (generalized linear model P < 0.05), with an effect at 600 lm peripheral to the center of the injury site (t-test with
Holms Bonferroni correction for multiple comparison at 600 lm P < 0.05). At the center of the injury site (0 lm), RGC death is not prevented by
siCASP2. In the distant periphery (1200 lm, 1800 lm), there is less RGC degeneration and no significant effect of siCASP2. (B) Photoreceptors are
not protected by siCASP2 (generalized linear model P > 0.05). ONL thickness is reduced after blunt ocular injury and siCASP2 does not improve
ONL thickness compared with siEGFP control. Experiments represent n¼ 8 animals per group; eight animals received bilateral blunt ocular trauma
with unilateral siCASP2 intravitreal injection and contralateral siEGFP control injection. n¼8 intact animals were used. Error bars represent SEM. (C,
D) Raw values in intact animals and after blunt ocular trauma with siCASP2 or siEGFP treatment for (C) mean BRN3A-positive cells per 1000 lm of
retinae and (D) mean ONL thickness (pixel count).
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suggests that rod photoreceptor function was not protected by
caspase-2 knockdown. Under photopic conditions, rod photo-
receptors are bleached, meaning the photopic a-wave is cone-
mediated. In rats, the photopic a-wave amplitude is small;
therefore, variations in b-wave amplitude were used as a
downstream measure of photoreceptor function, which is also
dependent on bipolar cell function. Under both scotopic and
photopic conditions, a-wave and b-wave amplitudes were
reduced after blunt ocular injury, but showed a lack of
functional improvement after siCASP2 treatment. These results
are consistent with the lack of effect of siCASP2 on ONL
thickness, suggesting that siCASP2 has no protective effect on
photoreceptor structure or function.
The photopic negative response (PhNR) is a downstream
measure of retinal function, dependent on activity in first and
second order neurons (photoreceptors and bipolar cells).50
Thus, a change in PhNR may be caused by changes in either
RGC function or upstream cells such as photoreceptors. The
PhNR is commonly used to assess RGC function; it is reduced in
experimental and human glaucoma51 and is correlated with
RGC loss in ON transection.52 Despite rat photopic responses
being heavily amacrine cell-dependent,53 a significant propor-
tion of the response is also RGC-dependent.52 Because siCASP2
treatment did not affect photopic b-wave amplitude, any change
in PhNR was derived from effects downstream of ON-bipolar
cells. siCASP2 increased PhNR amplitude at 14 days after injury
compared with siEGFP controls, suggesting that surviving RGCs,
in which caspase-2–dependent cell death was prevented, remain
potentially viable and functional. The elevated PhNR amplitude
could also reflect increased electrical activity in RGCs that are
dysfunctional but not dead, which would be consistent with the
>50% reduction in ERG amplitude after injury,41 despite <20%
photoreceptor degeneration, and the preservation of the PhNR
amplitude in siCASP2-injected eyes at near-normal levels.
Nonetheless, the improved PhNR amplitude raises the possibil-
ity that siCASP2 induces functional RGC neuroprotection after
blunt ocular trauma.
In conclusion, we show that in blunt ocular trauma,
caspase-2 mediates degeneration of a proportion of compro-
mised RGC and that siCASP2 provides functional neuroprotec-
tion to RGC peripheral to the injury site. By contrast, caspase-2
is not localized to photoreceptors and siCASP2-mediated
caspase-2 knockdown does not structurally or functionally
protect photoreceptors after retinal injury, suggesting that
caspase-2 is active exclusively in RGCs. Observations that
caspase-2 is activated in RGCs and neurons compromised in
other neurodegenerative diseases and in trauma33,35,38–40 imply
that caspase-2–dependent signaling pathways may be common
among CNS diseases and that siCASP2, if successful in clinical
trials, has the potential to be a widely transferable therapy.
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